Based: Prospect, Kentucky
Year founded: 2017
Founder(s)/top executives: Riya Shah, president
Capital raised to date: About $3 million (including grants)
Key investors: Former Kentucky Governor Matt Bevin, Dr. Robert Robbins (ex-chairman of ZirMed), Jay Lawson (ex-division president of Stryker)
Number of employees: 3
Brief company description: Fetal Life is a pregnancy medical device company based in Kentucky. Our vision is to help improve pregnancy outcomes worldwide, especially for high-risk pregnancies. We also want to help mitigate access-to-care issues, lack of resources issues and healthcare costs for rural and underserved pregnant populations. At Fetal Life, we believe in revolutionizing maternal care to help improve pregnancy outcomes worldwide through our patented and innovative products.
What is your company working on right now? Fetal Life is currently focused on product development and launch as well as raising further capital.
What’s on the horizon for your company in 2024? In 2024, Fetal Life is focused on the FDA compliance journey for the myFetalTronics device. We have successfully completed biocompatibility testing, and are in the process of completing EMC testing and usability studies. We are also exploring partnership opportunities in the Democratic Republic of Congo, Ghana and Saudi Arabia.
Why grow your company in/from Kentucky? Kentucky’s supportive and thriving entrepreneurial ecosystem helps entrepreneurs of all ages and backgrounds to grow their startups and achieve their entrepreneurial dreams.
Give us one bold prediction in 2024 for startups, technology or venture capital/fundraising. A bold prediction for medical devices startups in 2024 is the widespread emergence of advanced, AI-driven diagnostic devices that can revolutionize personalized wellness and care. These devices would integrate AI and machine learning algorithms to analyze complex medical data, enabling quicker and more accurate disease detection, prognosis and treatment recommendations. The convergence of AI and health care is set to redefine the landscape of medical device startups in 2024, with medical devices becoming powerful tools for making data-driven decisions to help improve patient outcomes.
